Impact of primary prevention and chemoprevention on the promotion of prostate cancer and the risk of developing clinically manifested prostate cancer: A prospective cohort study

Impact of primary prevention and chemoprevention on the promotion of prostate cancer and the risk of developing clinically manifested prostate cancer: A prospective cohort study - A Cohort study investigating the impact of primary prevention on the development of prostate cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000017789

Enrollment

800

Registered

2015-06-10

Start date

2015-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer

Interventions

None listed

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Men aged between 35 and 54 who participate in PSA screening within a thorough medical checkup and agree to participate after informed consent.

Exclusion criteria

Exclusion criteria: 1) having past or present history of prostate cancer 2) having severe complications (caridiac disease, interstitial pneumonia, bleeding tendency, uncontrollable hypertension, diabetes mellitus, etc.) 3) having uncontrolled other malignant disease (excluding carcinoma in situ, skin cancer and no evidence of recurrence more than 3 years after the treatment) 4) having any inappropriate factor judged by investigators

Design outcomes

Primary

Measure	Time frame
Changes in tumor marker (PSA, ratio of free to total PSA) and developing clinically manifested prostate cancer	—

Countries

Japan

Contacts

Public ContactRie Suzuki

Gunma University Urology

rsuzuki@gunma-u.ac.jp027-220-8303

Outcome results